Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “GEP Neuroendocrine Tumor”

121 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 121 results

Not applicableLooking for participantsNCT06402695
What this trial is testing

Observational Study on GEP-and Pulm-NET Treated at FPG

Who this might be right for
Neuroendocrine TumorsGep NetPulmonary Neuroendocrine Neoplasm
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 650
Testing effectiveness (Phase 2)Study completedNCT03043664
What this trial is testing

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Duke University 22
Large-scale testing (Phase 3)Looking for participantsNCT07165886
What this trial is testing

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 298
Testing effectiveness (Phase 2)Study completedNCT02162446
What this trial is testing

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 12
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Not applicableNot Yet RecruitingNCT07635316
What this trial is testing

Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 4,023
Testing effectiveness (Phase 2)Study completedNCT03147404
What this trial is testing

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Who this might be right for
Neuroendocrine Carcinoma, Grade 3
Samsung Medical Center 14
Early research (Phase 1)Looking for participantsNCT06732505
What this trial is testing

A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens

Who this might be right for
Neuroendocrine Neoplasm
Peking University Cancer Hospital & Institute 36
Large-scale testing (Phase 3)Ended earlyNCT01755182
What this trial is testing

Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
National Cancer Institute, Naples 1
Testing effectiveness (Phase 2)UnknownNCT03963193
What this trial is testing

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Who this might be right for
Gastrointestinal Neuroendocrine Tumor
Henan Cancer Hospital 112
Testing effectiveness (Phase 2)Active Not RecruitingNCT05988918
What this trial is testing

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Who this might be right for
Pancreatic AdenocarcinomaAdenosquamous CarcinomaPancreatic Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT03891784
What this trial is testing

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Who this might be right for
Advanced Digestive System Neuroendocrine NeoplasmDigestive System Neuroendocrine TumorForegut Neuroendocrine Tumor+6 more
University of Washington 20
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Early research (Phase 1)Not Yet RecruitingNCT07488923
What this trial is testing

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Who this might be right for
Small Cell Lung Cancer (SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic NEC (GEP NEC)+1 more
Moonlight Bio, Inc 110
Not applicableLooking for participantsNCT05196087
What this trial is testing

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Who this might be right for
Breast CancerMelanomaGastrointestinal Neuroendocrine Tumor
University Health Network, Toronto 500
Testing effectiveness (Phase 2)Looking for participantsNCT04837885
What this trial is testing

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

Who this might be right for
Neuroendocrine TumorLiver MetastasesNeuroendocrine Gastroenteropancreatic Tumour
University Hospital, Bordeaux 23
Very early researchActive Not RecruitingNCT04544098
What this trial is testing

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Who this might be right for
Neuroendocrine TumorsLiver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center 10
Testing effectiveness (Phase 2)Looking for participantsNCT05773274
What this trial is testing

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Who this might be right for
Metastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)
Post-approval studies (Phase 4)WithdrawnNCT02779257
What this trial is testing

Pasireotide Treatment for Neuroendocrine Tumor

Who this might be right for
Gastro-enteropancreatic Neuroendocrine Tumor
University of Maryland, Baltimore
Not applicableActive Not RecruitingNCT04804371
What this trial is testing

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Health Network, Toronto 40
Load More Results
116
100